Axamon solution 15mg / ml, No. 10
Expiration Date: 11/2025
Russian Pharmacy name:
Аксамон раствор 15мг/мл, №10
diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies;
diseases of the central nervous system: bulbar paralysis and paresis; the recovery period of organic lesions of the central nervous system, accompanied by movement disorders;
intestinal atony.
S / c or i / m.
Doses and duration of treatment are determined individually, depending on the severity of the disease.
Diseases of the peripheral nervous system
Mono- and polyneuropathies of various origins, polyradiculopathy: s / c or i / m 5-15 mg 1-2 times a day, course 10-15 days (in severe cases - up to 30 days); further treatment is continued with the tablet form of the drug.
Myasthenia gravis and myasthenic syndrome: s / c or i / m 15-30 mg 1-3 times a day with a further transition to the tablet form. The general course of treatment is 1-2 months. If necessary, the treatment can be repeated several times with a break between courses of 1-2 months.
Diseases of the central nervous system
Bulbar paralysis and paresis: s / c or i / m 5-15 mg 1-2 times a day, course 10-15 days; then, if possible, they switch to a tablet form.
The recovery period for organic lesions of the central nervous system, accompanied by movement disorders: i / m 10-15 mg 1-2 times a day, course up to 15 days; then, if possible, they switch to a tablet form.
Treatment and prevention of intestinal atony
The initial dose is 10-15 mg 1-2 times a day for 1-2 weeks.
| Solution for intramuscular and subcutaneous administration | 1 ml |
| active substance: | |
| ipidacrine hydrochloride monohydrate (in terms of anhydrous) | 5 mg |
| 15 mg | |
| excipients: 0.1 M hydrochloric acid solution - up to pH 3; water for injection - up to 1 ml |
hypersensitivity to any component of the drug;
epilepsy;
extrapyramidal disorders with hyperkinesis;
angina pectoris, severe bradycardia;
bronchial asthma;
mechanical obstruction of the intestine or urinary tract;
vestibular disorders;
peptic ulcer of the stomach or duodenum in the acute stage;
children's age up to 18 years (there are no systematized data on the use in children).
With care: gastric ulcer and duodenal ulcer in remission; thyrotoxicosis; cardiovascular diseases; a history of obstructive respiratory diseases or acute respiratory diseases. If the patient has one of the listed diseases, it is imperative to consult a doctor before taking the drug.